Get started
Work

Ibrutinib, venetoclax plus CD20 monoclonal Ab: Initial results of OASIS II, a prospective randomized phase 2 trial in previously untreated mantle cell lymphoma patients.

Year: 2025
Type: conference-abstract
DOI: 10.1200/jco.2025.43.16_suppl.7044
Authors: Steven Le Gouill, Virginie de Wilde, Toby Andrew Eyre, Mary Callanan, Gandhi Laurent Damaj, Alexis Claudel, Chauchet Adrien, Roch Houot, Ronan Le Calloch, Victoria Cacheux, Marc Andre, Franck Morschhauser, Barbara Burroni, David John Lewis, Benoît Tessoulin, Aurore Touzart
Institutions: Institut Curie, Erasmus Hospital, Churchill Hospital, CHU Dijon Bourgogne, Centre Hospitalier Universitaire de Caen Normandie, Assistance Publique – Hôpitaux de Paris, Centre Hospitalier Universitaire de Besançon, Inserm, Centre Hospitalier Universitaire de Rennes, Microenvironment and B-cells: Immunopathology, Cell, Differentiation and Cancer, Université de Rennes, Centre Hospitalier de Cornouaille, Centre Hospitalier Universitaire de Clermont-Ferrand, CHU Dinant Godinne UCL Namur, Hôpital Claude Huriez, Centre de Recherche des Cordeliers, Hôpital Cochin, Derriford Hospital, University Hospitals Plymouth NHS Trust, Centre Hospitalier Universitaire de Nantes, Hôpital Necker-Enfants Malades
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W4410818349
Cites:
Cited by: 1
Related to: 10